<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597101</url>
  </required_header>
  <id_info>
    <org_study_id>RC-6059</org_study_id>
    <secondary_id>1UH3TR001372-01</secondary_id>
    <nct_id>NCT02597101</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes</brief_title>
  <official_title>Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nick Giannoukakis, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in&#xD;
      general represent important gaps in knowledge to better understand the etiopathogenesis of&#xD;
      T2D. Emerging evidence indicates that certain leukocyte populations serve as an important&#xD;
      nexus of T2D-associated inflammation. This novel and innovative clinical trial will test the&#xD;
      efficacy of a leukocyte-selective anti-inflammatory small drug as adjunctive therapy in&#xD;
      improving insulin sensitivity in obese, insulin-resistant type 2 diabetic subjects. This&#xD;
      trial also offers a first-in-kind opportunity to better understand the role of specific&#xD;
      leukocyte populations in type 2 diabetes. The drug's clinical profile suggests that it will&#xD;
      be well-tolerated with few, if any, side effects, and the existence of simple methods that&#xD;
      can indirectly measure its activity in vivo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes (T2D) is characterized by concomitant insulin resistance and pancreatic beta&#xD;
      cell dysfunction. Disease prevalence continues to increase around the globe and is currently&#xD;
      estimated to be at more than 385 million affected people. As many as 1 in 3 people in the&#xD;
      United States could have diabetes by the year 2050 with significant economic consequences. In&#xD;
      2014, 1 in 5 health care dollars was spent to support the care of patients at a total&#xD;
      estimated cost &gt; $245 billion. Overweight, insulin-resistant (IR) T2D individuals manifest a&#xD;
      chronic systemic inflammation which impairs beta cells and peripheral insulin sensitivity.&#xD;
      This systemic inflammation is associated with an atherogenic lipid profile and predisposes&#xD;
      individuals to higher risk for micro- and macro-vascular disease, irrespective of&#xD;
      well-controlled glycemia. Although a variety of pharmacologic approaches maintain daily&#xD;
      glycemic control, it is becoming evident that there is an urgent need to identify adjunctive&#xD;
      therapies to improve, insulin sensitivity, beta cell function, and HbA1c since they begin&#xD;
      deteriorating quite substantially by 5 years following initial treatment. Ideally, such&#xD;
      adjunctive therapies should be well-tolerated, easy to administer, should not promote&#xD;
      hypoglycemia and should also attenuate the systemic inflammation. The role of neutrophils in&#xD;
      T2D and metabolic inflammation represents an important gap in knowledge to better understand&#xD;
      inflammation in T2D especially since neutrophils are the most abundant leukocyte population&#xD;
      in humans and constitute the bulk of inflammatory leukocytes. Emerging evidence indicates&#xD;
      that neutrophils along with neutrophil-derived elastase serve as an important nexus of&#xD;
      T2D-associated inflammation. This trial offers a first-in-kind opportunity to better&#xD;
      understand the role of neutrophils in T2D diabetics. We hypothesise that inhibition of&#xD;
      neutrophil elastase (NE) will attenuate the chronic systemic background inflammation in&#xD;
      overweight and obese, IR T2D subjects and that the potential improvement in insulin&#xD;
      sensitivity and glucose control could concurrently facilitate functional maintenance and&#xD;
      induce the rescue of pancreatic beta cell mass.&#xD;
&#xD;
      To test the hypothesis, we propose a clinical trial that is comprised of the following two&#xD;
      aims:&#xD;
&#xD;
      Aim 1: To test whether orally-administered NEI adjunctive therapy in obese, IR T2D subjects&#xD;
      improves insulin sensitivity, glucoregulation and glycemic control. The primary endpoint is&#xD;
      the improvement of insulin sensitivity at 6 months compared to baseline, assessed by the&#xD;
      hyperinsulinemic-euglycemic clamp method. Secondary endpoints will include: i) Safety (rate&#xD;
      and severity of adverse events including hypoglycemia); ii) Glycemic and metabolic control&#xD;
      variables; iii) Assessment of functional beta cell mass (improvement in baseline oral glucose&#xD;
      tolerance test (OGTT) C-peptide levels and AUC, insulin secretion rate (ISR), body mass and&#xD;
      body fat-corrected insulin sensitivity; and iv) Changes in inflammatory variables.&#xD;
      Exploratory endpoints will include improvement of OGTT C-peptide (and C-peptide AUC)&#xD;
      trajectory, ISR trajectory, and decreased dose and dose frequency of background drugs.&#xD;
&#xD;
      Aim 2: To inform the changes in innate and cellular immunity conferred by the trial study&#xD;
      agents as a mechanistic approach to understanding the basis of potential efficacy. Evidence&#xD;
      of suppression of systemic inflammation will be examined during the trial. Changes in gene&#xD;
      expression of PBL and neutrophils may provide a signature of responder versus non-responder&#xD;
      status and/or of effect of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 15, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity at 6 Months From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome measure is the insulin sensitivity at 6 months from baseline, assessed by the hyperinsulinemic-euglycemic clamp method. This is calculated as the M/LBM. M/LBM = whole-body insulin sensitivity adjusted for lean body mass. M/LBM is calculated as the steady-state glucose disposal (in mL) per kilogram lean body mass divided by steady-state insulin concentrations (micro IU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of All Adverse Events Including Hypoglycemia</measure>
    <time_frame>12 months</time_frame>
    <description>Severity of all adverse events including hypoglycemia based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 severity grade score (0-4). Higher scores indicate a worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Known AEs of AZD9668</measure>
    <time_frame>12 months</time_frame>
    <description>Attribution score of AE to known AEs of AZD9668 in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Known AEs of Saxagliptin</measure>
    <time_frame>12 months</time_frame>
    <description>Attribution score of AE to known AEs of saxagliptin in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Known AEs of Metformin</measure>
    <time_frame>12 months</time_frame>
    <description>Attribution score of AE to known AEs of metformin in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycated HbA1c Levels Compared to Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in the value of HbA1c study end (12 months) compared to baseline value (time 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OGTT From Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>The difference of the calculated area under the curve of the 2 hour OGTT test (AUC is the value of the area under the glucose concentration time curve) at 12 months minus the AUC at baseline (time zero). This AUC is calculated as the concentration of glucose versus time curve and the reporting units are mcg*dL/hour. The trapezoid rule was applied to the curve to obtain the AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OGTT-derived Insulinogenic Index Using C-peptide</measure>
    <time_frame>12 months</time_frame>
    <description>The change from baseline at 12 months where the insulinogenic index = ratio of fasting C-peptide concentration (ng/mL)/fasting glucose (ng/mL) at the time of the OGTT test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Serum Levels of Inflammatory Markers</measure>
    <time_frame>12 months</time_frame>
    <description>Serum levels refers to the concentration in serum of each of the analytes in the multi-analyte assay (Luminex) in terms of pg/mL depending on the analyte measured. We are reporting the difference in these values between 12 months and baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9668</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>background drug</description>
    <arm_group_label>AZD9668</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>background drug</description>
    <arm_group_label>AZD9668</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>study drug</description>
    <arm_group_label>AZD9668</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for AZD9668 to be added to background drugs</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Patients 21-75 years of age inclusive who meet the American Diabetes Association&#xD;
             standard criteria for type 2 diabetes mellitus (T2D).&#xD;
&#xD;
          2. Subjects are currently on metformin (at least 1000 mg per day) for a minimum period of&#xD;
             4 weeks prior to screening visit alone, or in combination with any of the following&#xD;
             diabetes medications or combinations:&#xD;
&#xD;
               1. DPPIV inhibitor (any dose level/frequency)&#xD;
&#xD;
               2. Sulfonylurea (any dose level/frequency)&#xD;
&#xD;
               3. GLP1 agonist (any dose level/frequency)&#xD;
&#xD;
               4. Sulfonylurea (any dose level/frequency) + GLP1 agonist (any dose level/frequency)&#xD;
&#xD;
               5. Meglitinide (any dose level/frequency)&#xD;
&#xD;
               6. SGLT2 inhibitor (any dose level/frequency)&#xD;
&#xD;
          3. Patients must have a body-to-mass index (BMI) of greater than or equal to 27 kg/m2.&#xD;
&#xD;
          4. Patients exhibit glycated HbA1c between 7.3-11.0 during eligibility screening and then&#xD;
             &lt;=8.5 at final run-in visit.&#xD;
&#xD;
          5. Willingness to replace current diabetes therapies (listed in inclusion 2) with&#xD;
             metformin and saxagliptin and to adjust metformin dose during run-in period.&#xD;
&#xD;
          6. Subjects present adequate immune competence as assessed by immunoreactivity to viral&#xD;
             antigens (CEF Pool Assay) in vitro at the time of screening.&#xD;
&#xD;
          7. Participants of childbearing potential must agree to practice an effective form of&#xD;
             birth control which may include any one of the following: barrier method, oral&#xD;
             contraception, or surgery. These measures must be maintained throughout the study.&#xD;
&#xD;
          8. Subjects must have good peripheral venous access for the hyperinsulinemic-euglycemic&#xD;
             clamp and the 3-hr. OGTT procedures.&#xD;
&#xD;
          9. Patients understand the study procedures, alternative treatments available, risks&#xD;
             involved in the study, and voluntarily agree to participate by giving informed and&#xD;
             signed written consent for screening and enrollment.&#xD;
&#xD;
         10. Participants can be on anti-inflammatory therapies that are not diabetes-focused (e.g.&#xD;
             non-salicylate anti-inflammatory therapies, non-salicylate NSAIDs) and/or&#xD;
             anti-hypertensive medicaments or statins.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Patients with type 1 diabetes mellitus as defined by the American Diabetes Association&#xD;
             criteria or a history of ketoacidosis, or the patients are assessed by the study team&#xD;
             as possibly having type 1 diabetes mellitus confirmed with the presence of at least&#xD;
             one of the typical autoantibodies (insulin, GAD65, IA-2, ZnT8) AND a serum C-peptide&#xD;
             level of &lt;0.7 ng/mL.&#xD;
&#xD;
          2. Patients have been treated with any therapies specific for their diabetes (other than&#xD;
             those listed in the inclusion criteria) within 4 weeks of the screening visit.&#xD;
&#xD;
          3. Patients have been treated with insulin within 2 months of the screening visit.&#xD;
&#xD;
          4. Patients are currently participating in or have participated in another study with an&#xD;
             investigational compound or device within the prior 12 weeks of signing the informed&#xD;
             consent or do not agree to refrain from participating in any other study while&#xD;
             participating in this study.&#xD;
&#xD;
          5. Patients have a history of hypersensitivity or any contraindication to DPPIV&#xD;
             inhibitors, including saxagliptin (Onglyza), or metformin based upon the labels of the&#xD;
             USA.&#xD;
&#xD;
          6. Patients are on a weight loss medication (such as orlistat, phentermine, Qsymia, or&#xD;
             Belviq) within the prior 6 weeks.&#xD;
&#xD;
          7. Patients are required by treating physicians to remain on any one of these agents&#xD;
             during the trial:&#xD;
&#xD;
             macrolide antibiotics, cisapride, anti-arrhythmics, steroids, rifampicin,&#xD;
             phenobarbital, phenytoin, secobarbital, carbamazepine, norethindrone, isoniazid.&#xD;
             AZD9668 is metabolized by CYP3A4, 3A5, and 2B6. SAXA is metabolized by CYP3A4 and 3A5,&#xD;
             potentially leading to drug-drug interactions with hypothetical adverse events in&#xD;
             patients on the above agents. Also, AZD9668 causes weak inhibition of CYP2C9 and&#xD;
             therefore patients on fluconazole, amiodarone, fenofibrate, fluvoxamine,&#xD;
             phenylbutazone, probenecid, sertraline, will also be excluded to avoid the&#xD;
             hypothetical adverse events due to this effect.&#xD;
&#xD;
          8. Patients have undergone major surgery within the 6 weeks prior to signing consent or&#xD;
             have any type or form of major surgery planned during the study (at the discretion of&#xD;
             the physician).&#xD;
&#xD;
          9. Patients are on or are likely to require treatment with 14 consecutive days or&#xD;
             repeated courses of pharmacologic doses of corticosteroids or any other&#xD;
             immunomodulatory agent. For example, patients requiring chronic systemic&#xD;
             corticosteroids (does not include topical or inhaled corticosteroids). Exceptions are&#xD;
             over the counter non-salicylate NSAIDs.&#xD;
&#xD;
         10. Enrollment or history of enrollment in a drug, or biologic therapy clinical trial that&#xD;
             affects the immune system within the past 12 months (e.g., systemic immunosuppressive&#xD;
             pharmacologics, immunosuppressive cytokines, therapeutic immunomodulating antibodies,&#xD;
             therapeutic immunomodulating fusion proteins and/or cytokine receptor decoys as well&#xD;
             as any intervention and/or non-intervention induced immunodeficiencies).&#xD;
&#xD;
         11. Prior history of coronary artery disease (defined as myocardial infarction, angina,&#xD;
             bypass surgery, or angioplasty)&#xD;
&#xD;
         12. Prior history of arrhythmia (excludes premature beats)&#xD;
&#xD;
         13. Prior history of heart failure defined as i) symptomatic OR ii) pulmonary edema, leg&#xD;
             edema or low ejection fraction (&lt;40%)&#xD;
&#xD;
         14. Evidence of refractory chronic migraine (defined in ICHD-3 and Martelletti et al.).&#xD;
&#xD;
         15. History of persistent bradycardia within the last year prior screening visit (more&#xD;
             than three episodes in a calendar year of a heart rate &lt;60 beats per minute that&#xD;
             required hospitalization on each of these occasions).&#xD;
&#xD;
         16. Leukopenia (&lt;3000 leukocytes/microliter), neutropenia (1500 neutrophils/microliter),&#xD;
             lymphopenia (&lt;800 lymphocytes/microliter), or thrombocytopenia (&lt;125000&#xD;
             platelets/microliter),. any other clinically relevant abnormal hematology value.&#xD;
&#xD;
         17. Positivity for HIV, active CMV, chlamydia, any evidence of serious fungal infection,&#xD;
             active HSV1and/or HSV2 (determined as IgM positivity of 2 standard deviations higher&#xD;
             than the highest value of the test reference range), hepatitis B or C, at screening.&#xD;
             Minor skin fungus, or minor candidiasis is not an enrollment or treatment exclusion&#xD;
             criterion. Also, with the exception of HIV history, hepatitis B and C,&#xD;
             successfully-treated, disease-free individuals (&gt; 6 months between time of successful&#xD;
             treatment confirmation and time at screening) would be eligible for enrollment in this&#xD;
             trial.&#xD;
&#xD;
         18. Patients are required by treating physician to remain on any medications listed in&#xD;
             inclusion #2 that directly affect glucose metabolism such as, but not limited to&#xD;
             thiazolidinediones, pramlintide, or amylin.&#xD;
&#xD;
         19. Vaccination with any form of live vaccine product within the last 3 months prior to&#xD;
             initiation of study agent administration.&#xD;
&#xD;
         20. Any chronic disease that in the opinion of the investigators would affect the&#xD;
             patient's safety and/or the integrity of the study outcome. This does not include&#xD;
             dyslipidemia, patients on statin or anti- hypertension treatment, or patients with&#xD;
             well-controlled hypo- or hyperthyroidism&#xD;
&#xD;
         21. Any other disease or disorder requiring chronic drug therapy except for treated&#xD;
             hypothyroidism (T4 and TSH should be within the normal reference range adjusted for&#xD;
             age), celiac disease, or statin- maintained, uncomplicated lipidemia.&#xD;
&#xD;
         22. Evidence of liver dysfunction, with ALT or AST&gt; 1.5 times the upper limit of normal.&#xD;
&#xD;
         23. Evidence of renal insufficiency as indicated by blood creatinine of &gt; 2 times the&#xD;
             upper limit of normal at baseline screening OR an eGFR &lt; 45 mL/min. OR A past history&#xD;
             or current clinical evidence of renal failure or low creatinine clearance at&#xD;
             screening.&#xD;
&#xD;
         24. Females who are pregnant at the time of screening or unwilling to defer pregnancy&#xD;
             during the study period.&#xD;
&#xD;
         25. Lactating women.&#xD;
&#xD;
         26. Poor accessibility to veins for the 3-hour OGTT and hyperinsulinemic-euglycemic clamp&#xD;
             procedures.&#xD;
&#xD;
         27. The following therapies cannot be administered while patients are undergoing treatment&#xD;
             on this protocol: i) radiation therapy; ii) chemotherapy; iii) corticosteroids (except&#xD;
             for very short courses of topical or inhaled); iv) agents used to treat attention&#xD;
             deficit and hyperactivity disorder (ADHD); v) rifampicin or phenytoin; vi) other&#xD;
             protein, particle or cell vaccine immunomodulation therapies. If these therapies are&#xD;
             essential for treatment of other conditions, participation in this study will be&#xD;
             terminated.&#xD;
&#xD;
         28. A condition which interferes with the ability to accurately determine glycated HbA1c.&#xD;
             Examples include: Genetic variants (e.g. HbS trait, HbC trait), elevated fetal&#xD;
             hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated&#xD;
             Hb in patients with renal failure); Any condition that shortens erythrocyte survival&#xD;
             or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic&#xD;
             anemia); Iron deficiency anemia, iron replacement therapy&#xD;
&#xD;
         29. Subjects who cannot tolerate at least 1000 mg daily of immediate or extended release&#xD;
             metformin by the time of final run-in will be excluded from further participation.&#xD;
&#xD;
         30. Subjects who do not exhibit a glycated HbA1c level &lt;=8.5 by the end of the run-in&#xD;
             period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Giannoukakis, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allegheny Health Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://projectreporter.nih.gov/project_info_description.cfm?aid=8996344&amp;icde=26920272</url>
    <description>NIH REPORTER INFORMATION</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <results_first_submitted>January 11, 2021</results_first_submitted>
  <results_first_submitted_qc>April 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</investigator_affiliation>
    <investigator_full_name>Nick Giannoukakis, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Immunology and Biological Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>While de-identified data (outcomes, measurements) from single study participants will be recorded and available through requests to the NIH, publicly-available data will be in the form of means, medians, and descriptive aggregate values representing the treatment groups in peer-reviewed publications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediate (as of January 29, 2021); available until January 31, 2031.</ipd_time_frame>
    <ipd_access_criteria>Upon request to the Study PI.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02597101/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>14 subjects consented (9 screen failures, 5 randomized). Of the 5 randomized, 4 completed both arms while 1 was withdrawn after completing the AZD9668 arm and did not crossover to placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
        </group>
        <group group_id="P2">
          <title>AZD9668</title>
          <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
        </group>
        <group group_id="B2">
          <title>AZD9668</title>
          <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Insulin sensitivity at baseline, assessed by the hyperinsulinemic-euglycemic clamp method.&#xD;
M/LBM = whole-body insulin sensitivity adjusted for lean body mass. M/LBM is calculated as the steady-state glucose disposal (in mL) per kilogram lean body mass divided by steady-state insulin concentrations (micro IU/mL).</description>
          <units>(ml/kg/min)/(microIU/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.05" spread="7.4"/>
                    <measurement group_id="B2" value="9.9" spread="3.3"/>
                    <measurement group_id="B3" value="8.975" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity at 6 Months From Baseline</title>
        <description>The primary outcome measure is the insulin sensitivity at 6 months from baseline, assessed by the hyperinsulinemic-euglycemic clamp method. This is calculated as the M/LBM. M/LBM = whole-body insulin sensitivity adjusted for lean body mass. M/LBM is calculated as the steady-state glucose disposal (in mL) per kilogram lean body mass divided by steady-state insulin concentrations (micro IU/mL).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity at 6 Months From Baseline</title>
          <description>The primary outcome measure is the insulin sensitivity at 6 months from baseline, assessed by the hyperinsulinemic-euglycemic clamp method. This is calculated as the M/LBM. M/LBM = whole-body insulin sensitivity adjusted for lean body mass. M/LBM is calculated as the steady-state glucose disposal (in mL) per kilogram lean body mass divided by steady-state insulin concentrations (micro IU/mL).</description>
          <units>(mL/kg/min)/(microIU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="3.7"/>
                    <measurement group_id="O2" value="6.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy endpoint is the improvement of insulin sensitivity by 40% or greater at 6 months compared to baseline, assessed by the hyperinsulinemic-euglycemic clamp method.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>REML mixed model</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Using REML mixed model analysis, differences between study arms resulting in a p&lt;0.05 would represent statistically-significant differences.</p_value_desc>
            <method>REML mixed model</method>
            <param_type>REML mixed model</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of All Adverse Events Including Hypoglycemia</title>
        <description>Severity of all adverse events including hypoglycemia based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 severity grade score (0-4). Higher scores indicate a worse severity.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of All Adverse Events Including Hypoglycemia</title>
          <description>Severity of all adverse events including hypoglycemia based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 severity grade score (0-4). Higher scores indicate a worse severity.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Known AEs of AZD9668</title>
        <description>Attribution score of AE to known AEs of AZD9668 in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Known AEs of AZD9668</title>
          <description>Attribution score of AE to known AEs of AZD9668 in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Known AEs of Saxagliptin</title>
        <description>Attribution score of AE to known AEs of saxagliptin in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Known AEs of Saxagliptin</title>
          <description>Attribution score of AE to known AEs of saxagliptin in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Known AEs of Metformin</title>
        <description>Attribution score of AE to known AEs of metformin in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Known AEs of Metformin</title>
          <description>Attribution score of AE to known AEs of metformin in terms of an atribution scale of 0-4. The scale is defined as: Score 0=Unrelated; Score 1=The AE is unlikely related; Score 2=The AE has a reasonable possibility to be related; Score 3=The AE is likely related; Score 4=The AE is clearly related</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycated HbA1c Levels Compared to Baseline</title>
        <description>Difference in the value of HbA1c study end (12 months) compared to baseline value (time 0)</description>
        <time_frame>12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycated HbA1c Levels Compared to Baseline</title>
          <description>Difference in the value of HbA1c study end (12 months) compared to baseline value (time 0)</description>
          <population>ITT</population>
          <units>percentage of the change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.4"/>
                    <measurement group_id="O2" value="7.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OGTT From Baseline</title>
        <description>The difference of the calculated area under the curve of the 2 hour OGTT test (AUC is the value of the area under the glucose concentration time curve) at 12 months minus the AUC at baseline (time zero). This AUC is calculated as the concentration of glucose versus time curve and the reporting units are mcg*dL/hour. The trapezoid rule was applied to the curve to obtain the AUC.</description>
        <time_frame>12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OGTT From Baseline</title>
          <description>The difference of the calculated area under the curve of the 2 hour OGTT test (AUC is the value of the area under the glucose concentration time curve) at 12 months minus the AUC at baseline (time zero). This AUC is calculated as the concentration of glucose versus time curve and the reporting units are mcg*dL/hour. The trapezoid rule was applied to the curve to obtain the AUC.</description>
          <population>ITT</population>
          <units>mcg*dL/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="732.9" spread="156.6"/>
                    <measurement group_id="O2" value="821.4" spread="185.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OGTT-derived Insulinogenic Index Using C-peptide</title>
        <description>The change from baseline at 12 months where the insulinogenic index = ratio of fasting C-peptide concentration (ng/mL)/fasting glucose (ng/mL) at the time of the OGTT test.</description>
        <time_frame>12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OGTT-derived Insulinogenic Index Using C-peptide</title>
          <description>The change from baseline at 12 months where the insulinogenic index = ratio of fasting C-peptide concentration (ng/mL)/fasting glucose (ng/mL) at the time of the OGTT test.</description>
          <population>ITT</population>
          <units>ratio of fasting C-peptide concentration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="2.2"/>
                    <measurement group_id="O2" value="22.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Serum Levels of Inflammatory Markers</title>
        <description>Serum levels refers to the concentration in serum of each of the analytes in the multi-analyte assay (Luminex) in terms of pg/mL depending on the analyte measured. We are reporting the difference in these values between 12 months and baseline.</description>
        <time_frame>12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
          </group>
          <group group_id="O2">
            <title>AZD9668</title>
            <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Serum Levels of Inflammatory Markers</title>
          <description>Serum levels refers to the concentration in serum of each of the analytes in the multi-analyte assay (Luminex) in terms of pg/mL depending on the analyte measured. We are reporting the difference in these values between 12 months and baseline.</description>
          <population>ITT</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eoatxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="20.9"/>
                    <measurement group_id="O2" value="39.2" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="0.3"/>
                    <measurement group_id="O2" value="8.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INFa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="4.6"/>
                    <measurement group_id="O2" value="18.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1RA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="14.6"/>
                    <measurement group_id="O2" value="87.6" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.1"/>
                    <measurement group_id="O2" value="5.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.6" spread="94.9"/>
                    <measurement group_id="O2" value="167.1" spread="107.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="1.1"/>
                    <measurement group_id="O2" value="22.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.1"/>
                    <measurement group_id="O2" value="4.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.7"/>
                    <measurement group_id="O2" value="3.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="8.2"/>
                    <measurement group_id="O2" value="9.0" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.0"/>
                    <measurement group_id="O2" value="8.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="0.4"/>
                    <measurement group_id="O2" value="11.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="12.1"/>
                    <measurement group_id="O2" value="43.4" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="1.8"/>
                    <measurement group_id="O2" value="12.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="14.4"/>
                    <measurement group_id="O2" value="47.7" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="0.8"/>
                    <measurement group_id="O2" value="10.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INFy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="4.7"/>
                    <measurement group_id="O2" value="17.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="17.2"/>
                    <measurement group_id="O2" value="19.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="29.5"/>
                    <measurement group_id="O2" value="93.5" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="9.4"/>
                    <measurement group_id="O2" value="22.1" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="2.2"/>
                    <measurement group_id="O2" value="14.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="27.9"/>
                    <measurement group_id="O2" value="81.5" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RANTES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532.6" spread="612.5"/>
                    <measurement group_id="O2" value="219.5" spread="125.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="3.3"/>
                    <measurement group_id="O2" value="10.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The definition of AE/SAE used to collect AE information does not differ from the clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
placebo: placebo for AZD9668 to be added to background drugs</description>
        </group>
        <group group_id="E2">
          <title>AZD9668</title>
          <description>60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)&#xD;
Metformin: background drug&#xD;
saxagliptin: background drug&#xD;
AZD9668: study drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The failure to enroll a critical mass of study subjects renders the outcome difficult to interpret given the inability to conduct statistical analyses that would be more meaningful.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nick Giannoukakis</name_or_title>
      <organization>Allegheny Health Network</organization>
      <phone>412-359-6394</phone>
      <email>nick.giannoukakis@ahn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

